Eurocine Vaccines discloses year-end report for the fiscal year 2021/2022

Highlights during the fiscal year

Fourth quarter (2022-04-01 - 2022-06-30)

Eurocine Vaccines expanded its portfolio with a therapeutic HSV-2 vaccine candidate

In June 2022, Eurocine Vaccines announced that the company has entered into a research and collaboration agreement with Redbiotec AG. The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccines candidates against Herpes Simplex Virus Type 2, HSV-2, based on the technologies developed by Redbiotec.

Third quarter (2022-01-01 - 2022-03-31)

Eurocine Vaccines' options of series TO 4 were exercised

In March 2022, Eurocine Vaccines announced that approximately 84.5 percent of the TO 4 warrants were exercised at the subscription price 1.41 SEK per share. Including the subscription and guarantee commitments from the main owner Flerie Invest, Eurocine Vaccines received the total amount of approximately SEK 4.5 million before issuing costs. The new shares were registered in April 2022.

Second quarter (2021-10-01 - 2021-12-31)

Eurocine Vaccines' chlamydia vaccine candidate elicits both antibody and T cell responses

In December 2021, Eurocine Vaccines announced new preclinical study results, showing that intramuscular immunization with the chlamydia vaccine candidate elicits an excellent T cell response, in addition to the previously confirmed antibody responses. Achieving this combination of antibodies and T cells indicates that the company's vaccine candidate generates an effective barrier, which can prevent infection as well as promote clearance of infected cells.

Eurocine Vaccines resolved on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application

In December 2021, the Board of Directors of Eurocine Vaccines resolved to request scientific advice from the Swedish Medical Products Agency ahead of submitting the clinical trial application with the company's vaccine candidate against Chlamydia. The scientific advice aims to strengthen Eurocine Vaccines' documentation and maximize the probability of a swift approval of the application.

Eurocine Vaccines announced change in ownership structure

In October 2021, Eurocine Vaccines announced that Flerie Invest AB had acquired shares in the company and held above 10 % of the shares. Flerie Invest AB held in October approximately 12.55 % of the votes and capital. Further, Eurocine Vaccines announced that Formue Nord Markedsneutral A/S had decreased its holdings to approximately 3.09 % of the votes and capital.

Eurocine Vaccines held Annual General Meeting

In December 2021, Eurocine Vaccines held its Annual General Meeting. A summary of the resolutions is available on Eurocine Vaccines website, Communiqué from AGM (https://www.eurocine-vaccines.com/kommunike-fran-arsstamma-i-eurocine-vaccines-ab-publ/) (in Swedish).

First quarter (2021-07-01 - 2021-09-30)

Eurocine Vaccines extended its product portfolio with a diagnostic test of chlamydia through a widened agreement with Spixia Biotechnology

In August 2021, Eurocine Vaccines AB decided to evaluate a diagnostic test of chlamydia antibodies in blood as an extension of its portfolio and has widened the license agreement with Spixia Biotechnology AB to also include diagnostic tests of chlamydia.

Highlights after the end of the fiscal year

Eurocine Vaccines outlines a strategic development plan for its newly added therapeutic HSV-2 vaccine candidate

In July 2022, Eurocine Vaccines outlined a strategic development plan. The HSV-2 project offers a series of possibilities regarding the choice of technology and the opportunity it may give to pursue the therapeutic vaccine candidate with a prophylactic candidate to follow.

Disclosure notice in Eurocine Vaccines

In July 2022, Eurocine Vaccines announced that Flerie Invest AB has acquired shares in the company and now holds more than 15% of the shares. Flerie Invest AB holds approximately 16.12% of the votes and capital. Flerie Invest AB is a well renowned Swedish investment company within the biotechnology and life science sector, and was founded in 2010 by Thomas Eldered, co-founder of Recipharm.

CEO Hans Arwidsson

We can look back on an intense and evolving fiscal year 2021/2022 for Eurocine Vaccines. The recent development of our innovative vaccine candidate portfolio makes me confident that we are well positioned to improve the quality of life and reduce suffering for millions of patients, an ambitious goal that we now continue working towards into the new fiscal year.

We have made important progress with our chlamydia vaccine candidate, including a preclinical study in late 2021 that confirmed that the candidate generates both antibodies and T cells. This indicates that it has great potential to prevent infection as well as efficiently heal an infection that has already begun. The extensive and intense work to develop av industrial manufacturing method for the active protein has also been pursued professionally by the team for the future toxicological and clinical studies.

In addition to the development of the chlamydia vaccine candidate, much of our work has focused on expanding our portfolio of innovative vaccine candidates. We are therefore very pleased to have

completed the financial year with the addition of a therapeutic vaccine candidate against Herpes Simplex Virus type 2, HSV-2, to the vaccine portfolio. The research and collaboration agreement we have entered with Redbiotec AG gives us exclusive global rights to develop, manufacture and commercialize vaccine candidates against HSV-2, based on Redbiotec's technology. Their scientific progress is impressive, and I am very pleased that we have added such a promising candidate to our portfolio, perfectly in line with our strategy. Even though we will focus on the therapeutic candidate, the agreement also covers prophylactic vaccines based on proteins as well as mRNA.

Our newly expanded portfolio means that we are facing an intense fall of planning and evaluating the HSV-2 candidate through preclinical studies, which will e.g. generate results to decide on the technology to be used in the further development - protein or mRNA. In parallel, we conduct an early evaluation of a prophylactic vaccine candidate. Our work with the chlamydia vaccine candidate is progressing and we are preparing to produce study products for our upcoming toxicology study and to plan the phase I clinical trial in further detail. In connection with all development work, aspects of patents and business development are constantly present.

During the spring, we successfully completed the warrant exercise. I would once again like to thank everyone who chose to exercise their TO 4. The subscription rate of approximately 84.5 percent together with the support of Flerie Invest enabled us to achieve 100 percent of the issue volume and we are now well financially positioned for our near-term goals.

Finally, I would like to thank all shareholders in Eurocine Vaccines for your continued trust. We have an exciting year ahead of us with the development of two very promising vaccine candidates against chlamydia and Herpes Simplex Virus type 2, HSV-2, both with impressive market potential. Together with the team, I am looking forward to a fall where we will continue to develop the chlamydia vaccine candidate and to start the first preclinical studies on the vaccine candidate against HSV-2.

Please join us for upcoming activities, which will appear in our Calendar (https://www.eurocine-vaccines.com/events/), and see our latest presentation, Småbolagsdagarna in Stockholm on 15 June 2022 (https://www.youtube.com/watch?v=-gWnSiG2dZQ) (in Swedish).

Hans Arwidsson - CEO, Eurocine Vaccines AB